Viveve Medical, Inc. Announces Closing of $15.5 Million Initial Public Offering
MSK client Viveve Medical, Inc. ("Viveve") (Nasdaq:VIVE), a medical technology company focused on women’s health, has proudly announced the closing of its initial public offering (IPO) of 3,105,000 shares of common stock, including the exercise of the underwriters’ over-allotment option, at a price to the public of $5.00 per share, for aggregate gross proceeds of approximately $15.5 million. In connection with the IPO, Viveve also uplisted to the NASDAQ Capital Market.
MSK served as Viveve’s legal counsel in the IPO and was led by Melanie Figueroa, Managing Partner of the firm's New York office. The MSK team also included Kevin Friedmann, Chairman of MSK's Corporate & Business Transactions Department, Gabrielle Napolitano and Louisa Zhou.
"We are proud to have served as Viveve’s counsel in connection with its IPO and to assist it in achieving this major milestone," stated Ms. Figueroa. “Viveve has been a client for many years and we have watched them grow through successive private placements. Being a part of Viveve’s IPO is extremely gratifying. We are excited to participate in Viveve’s journey as it continues to grow and gain recognition in the women’s health industry," Ms. Figueroa concluded.
Media contact:
Doug Gold, Chief Marketing Officer
310.312.3712
